Recently, immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 (PD-1)- and -programmed death-ligand 1 (PD-L1) monoclonal antibodies (mAbs) have markedly changed the treatment of several types of cancer, significantly improving patient survival and quality-of-life [12]. This evidence concerns the gene CD274 and cancer.